


## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
MA-81  
APPLICATION NO.  
09/717,563  
APPLICANT  
DUBOWCHIK ET AL.  
FILING DATE  
NOVEMBER 21, 2000

Sheet 1 of 3

RECEIVED

APR 17 2001

TECH CENTER Group -  
1600/2900

#7

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
A.K.	AA	5,622,970	4/22/97	D. Armistead, et al			
	AB	5,330,993	7/19/94	D. Armistead, et al			
	AC	5,192,773	3/9/93	D. Armistead, et al			
	AD	5,516,797	5/14/96	D. Armistead, et al			
	AE	5,696,135	12/9/97	J. P. Steiner, et al			
	AF	5,721,256	2/24/98	G. S. Hamilton, et al			
	AG	5,654,332	8/5/97	D. Armistead			
	AH	5,780,484	7/14/98	R. E. Zelle, et al			
	AI	5,786,378	7/28/98	G. S. Hamilton, et al			
	AJ	5,795,908	8/18/98	G. S. Hamilton, et al			
	AK	5,798,355	8/25/98	J. P. Steiner, et al			
	AL	5,801,187	9/1/98	Jia-He Li, et al			
	AM	5,801,197	9/1/98	J. P. Steiner, et al			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
A.K.	AN	WO 94/07858	4/14/94	PCT Application			<input type="checkbox"/>	<input type="checkbox"/>
	AO	WO 92/19593	11/12/92	PCT Application			<input type="checkbox"/>	<input type="checkbox"/>
	AP	WO 92/21313	12/10/92	PCT Application			<input type="checkbox"/>	<input type="checkbox"/>
	AQ	EP 564924B1	10/13/93	European Patent Application			<input type="checkbox"/>	<input type="checkbox"/>
	AR	EP 405994A2	1/2/91	European Patent Application			<input type="checkbox"/>	<input type="checkbox"/>
	AS	WO 96/40140	12/19/96	PCT Application			<input type="checkbox"/>	<input type="checkbox"/>
	AT	WO 96/40633	12/19/96	PCT Application			<input type="checkbox"/>	<input type="checkbox"/>
	AU	WO 97/16190	5/9/97	PCT Application			<input type="checkbox"/>	<input type="checkbox"/>
	AV	WO 96/41609	12/27/96	PCT Application			<input type="checkbox"/>	<input type="checkbox"/>
	AW	WO 97/36869	10/9/97	PCT Application			<input type="checkbox"/>	<input type="checkbox"/>
	AX	WO 98/13343	4/2/98	PCT Application			<input type="checkbox"/>	<input type="checkbox"/>
	AY	WO 98/13355	4/2/98	PCT Application			<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

## INFORMATION DISCLOSURE CITATION

ATTY. DOCKET NO.  
MA-81  
APPLICATION NO.  
09/717,563  
APPLICANT  
DUBOWCHIK ET AL.  
FILING DATE  
NOVEMBER 21, 2000

Group -



(Use several sheets if necessary)

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
B.K.	AZ	WO 98/20891	5/22/98	PCT Application			<input type="checkbox"/>	<input type="checkbox"/>
	BA	WO 98/20892	5/22/98	PCT Application			<input type="checkbox"/>	<input type="checkbox"/>
	BB	WO 98/20893	5/22/98	PCT Application			<input type="checkbox"/>	<input type="checkbox"/>
	BC	WO 98/29116	7/9/98	PCT Application			<input type="checkbox"/>	<input type="checkbox"/>
	BD	WO 98/29117	7/9/98	PCT Application			<input type="checkbox"/>	<input type="checkbox"/>
	BE	WO 99/10340	3/4/99	PCT Application			<input type="checkbox"/>	<input type="checkbox"/>
	BF	WO 99/21552	5/6/99	PCT Application			<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

B.K.	BG	A. Ruhlmann, et al, "Effects of the Immunosuppressive Drugs CsA and FK506 on Intracellular Signalling and Gene Regulation," IMMUNOBIOLOGY, <b>198</b> , pp. 192-206, 1997
	BH	S. L. Schreiber, et al, "Molecular Recognition of Immunophilins and Immunophilin-Ligand Complexes," TETRAHEDRON, <b>48</b> (13), pp. 2545-2558, 1992
	BI	T. Wang, et al, "Specific Interaction of Type I Receptors of the TGF- $\beta$ Family with the Immunophilin FKBP-12," SCIENCE, <b>265</b> , pp. 674-676, 1994
	BJ	A. M. Cameron, et al, "FKBP12 Binds the Inositol 1,4,5-Trisphosphate Receptor at Leucine-Proline (1400-1401) and Anchors Calcineurin to This FK506-Like Domain," J. BIOLOGICAL CHEMISTRY, <b>272</b> (44), pp. 27582-27588, 1997
	BK	T. Wang, et al, "The Immunophilin FKBP12 Functions as a Common Inhibitor of the TGF $\beta$ Family Type I Receptors," CELL, <b>86</b> , pp. 435-444, 1996
	BL	D. S. Yamashita, et al, "Design, Synthesis and Evaluation of Dual Domain FKBP Ligands," BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, <b>4</b> (2), pp. 325-328, 1994
	BM	D. M. Armistead, et al, "Design, Synthesis and Structure of Non-Macrocyclic Inhibitors of FKBP12, the Major Binding Protein for the Immunosuppressant FK506," ACTA CRYST., <b>D51</b> , pp. 522-528, 1995
	BN	W. E. Lyons, et al, "Immunosuppressant FK506 Promotes Neurite Outgrowth in Cultures of PC12 Cells and Sensory Ganglia," PROC. NATL. ACAD. SCI. USA, <b>91</b> , pp. 3191-3195, 1994
	BO	B. G. Gold, et al, "The Immunosuppressant FK506 Increases the Rate of Axonal Regeneration in Rat Sciatic Nerve," J NEUROSCIENCE, <b>15</b> (11), pp. 7509-7516, 1995
	BP	G. S. Hamilton, et al, "Neuroimmunophilin Ligands as Novel Therapeutics for the Treatment of Degenerative Disorders of the Nervous System," CURRENT PHARMACEUTICAL DESIGN, <b>3</b> , pp. 405-428, 1997

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE  
**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.  
MA-81  
APPLICATION NO.  
09/717,563  
APPLICANT  
DUBOWCHIK ET AL.  
FILING DATE  
NOVEMBER 21, 2000

Sheet 3 of 3



RECEIVED  
APR 17 2001  
TECH CENTER 1600/2900

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

B.K.	BQ	B. S. Gold, et al, "A Nonimmunosuppressant FKBP-12 Ligand Increases Nerve Regeneration," EXPERIMENTAL NEUROLOGY, <b>147</b> , pp. 269-278, 1997
	BR	S. H. Snyder, et al, "Immunophilins and the Nervous System," NATURE MEDICINE, <b>1</b> (1), pp. 32-37, 1995
	BS	B. G. Gold, et al, "The Immunosuppressant FK506 Increases GAP-43 mRNA Levels in Axotomized Sensory Neurons," NEUROSCIENCE LETTERS, <b>241</b> , pp. 25-28, 1998
	BT	B. G. Gold, et al, "Immunophilin FK506-Binding Protein 52 (Not FK506-Binding Protein 12) Mediates the Neurotrophic Action of FK506," JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, <b>289</b> (3), pp. 1202-1210, 1999
	BU	C. T. Craescu, et al, "Three-Dimensional Structure of the Immunophilin-Like Domain of FKBP59 in Solution," BIOCHEMISTRY, <b>35</b> , pp. 11045-11052, 1996
	BV	J. R. Hauske, et al, "Investigation of the Effects of Synthetic, Non-Cytotoxic Immunophilin Inhibitors on MDR, BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, <b>4</b> (17), pp. 2097-2102, 1994
	BW	M. M. Endrich, et al, "The V3 Loop of Human Immunodeficiency Virus Type-1 Envelope Protein is a High-Affinity Ligand for Immunophilins Present in Human Blood," EUR. J. BIOCHEM., <b>252</b> , pp. 441-446, 1998
	BX	A. Karpas, et al, "Inhibition of Human Immunodeficiency Virus and Growth of Infected T Cells by the Immunosuppressive Drugs Cyclosporin A and FK 506." PROC. NATL. ACAD. SCI. USA, <b>89</b> , pp. 8351-8355, 1992

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.